Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer

Summary

This clinical trial will be conducted as a single-center, open-label, Phase I/2 trial to evaluate the feasibility and safety of Yttrium-90 radioembolization (Y90-RE) in combination with a fixed dose of of immunotherapy (durvalumab - 750 mg) in subjects with liver-predominant, metastatic colorectal cancer (mCRC), which is mismatch repair proficient/microsatellite stable (pMMR/MSS).

Timeline

Start

2020-10-05

Primary completion

2023-11-17

Completion

2023-11-17

Outcome

Outcome not reported

Stopped: “DSMC-directed closure”

Drugs

Indications